Coeptis Therapeutics, Inc. Acquires CD38 Tech from VyGen-Bio

Coeptis Therapeutics, Inc. is a pharmaceutical company focused on developing innovative technologies to break past traditional therapeutic paradigms. Recently, they have announced to exercise their option to acquire ownership in two technology assets that target CD38 cancers. These technologies come from VyGen-Bio, Inc. – a subsidiary of Vycellix, Inc. 

The first technology – a CD38-GEAR-NK – is a cell therapy product in development to protect CD38-NK (natural killer) cells from destruction. The second is CD38-Diagnostic, an in vitro diagnostic tool to help identify cancer patients who may be appropriate candidates for the anti-CD38 mAB therapy. 

This move follows Coeptis’ entry into two separate exclusive option agreements with VyGen-Bio, Inc. This co-development will help in their treatment of cancers associated with CD38 with the first indication expected to be multiple myeloma. 

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts